Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.
Tiantian Tang, Jingxuan Wang, Tao Sun, Lina Zhang, Fanfan Li, Bing Zhao, Guohui Han, Zhongsheng Tong, Hua Yang, Yongmei Yin, Xiangshun Kong, Ying Wang, Jianyun Nie, Lixia Ma, Yongqiang Zhang, Jing Luo, Changping Shan, Jing Yao, Shisheng Tan, Xiaoling Ling, Hongmei Sun, Huihui Li, Li Ma, Tao Zhou, Yunjiang Liu, Yixin Qi, Zhenchuan Song, Yuntao Li, Chao Yang, Tianli Hui, Meiqi Wang, Haoqi Wang, Xi Zhang, Wenhui Zhao, Yanhui Li, Mengmeng Li, Ying Xin, Xuan Luo, Deliang Yin, Hongmei Luo, Huan Liu, Qianyun Lu, Jing Yuan, Cuizhi Geng, Qingyuan Zhang
Biomol Biomed 10.17305/bb.2026.14334
摘要
摘要
SYHX2011 is a novel albumin-bound paclitaxel formulation designed to simplify drug preparation and reduce skin rash by replacing most non-particulate human serum albumin with mannitol and sucrose. This exploratory analysis evaluated updated survival outcomes after extended follow-up of a multicenter, randomized, double-blind, phase III trial comparing SYHX2011 with approved albumin-bound paclitaxel (PAB; Keaili®) in patients with unresectable locally advanced or metastatic breast cancer. Overall, 459 patients were randomized 1:1 to receive SYHX2011 or PAB. At the December 29, 2025 data cutoff, median follow-up was 25.2 and 25.0 months, respectively. Median progression-free survival (PFS) was 7.6 months with SYHX2011 and 5.6 months with PAB (p=0.028; hazard ratio [HR]=0.79, 95% confidence interval [CI]: 0.63-1.01). Median overall survival (OS) was not reached with SYHX2011 and was 24.3 months with PAB (p=0.11; HR=0.84, 95% CI: 0.64-1.11). Descriptive trends toward longer PFS and OS with SYHX2011 were observed across hormone receptor-positive, triple-negative, first-line, and later-line subgroups. Although OS data remain immature and subgroup findings require cautious interpretation, the updated results support continued clinical evaluation of SYHX2011 as an albumin-bound paclitaxel option for advanced breast cancer.
KM 提取结果
0 个 Figure · 0 个 KM 面板